Join the LinkedIn Group.
ASCPT Members-Only Webinar presented by the Biologics Community
: Development of Talimogene Laherparepvec, First FDA Approved Genetically Modified Oncolytic Virus: Perspectives of Clinical Pharmacology
Date and Time
: Tuesday, October 29, 2019, 2:00 pm ET
Speakers and Panelists
: Matt Hsu, PhD, Sumita Bhatta, MD, and Xiaofei Wang, PhD
: Yow-Ming Wang, PhD
Description: Talimogene laherparepvec is an oncolytic virus-based therapeutic product that is derived from herpes simplex virus type 1 (HSV-1). It has been genetically modified to efficiently replicate within tumors and to enhance systemic antitumor immune responses by producing the immune stimulatory protein granulocyte-macrophage colony-stimulating factor (GM-CSF). Clinical pharmacology program of talimogene laherparepvec was designed to characterize the kinetics of viral clearance through biodistribution in the blood and urine, shedding from injected tumors and exterior of the dressing, anti-HSV-1 seroconversion, and GM-CSF expression in tumor tissue and serum. This special presentation will provide an introduction of genetically modified products and regulatory advances in this field, as well as challenges and clinical pharmacology support of talimogene laherparepvec development pathway.
Registration Link: https://attendee.gotowebinar.com/register/2000518926673682691